EUCTR2012-002947-74-AT进行中（未招募）不适用
A prospective randomized, double blind, placebo-controlled, cross-over study to investigate the analgesic effect of Aspirin® to prevent the pain during the treatment with capsaicin patch 8% (Qutenza®) - Clinical trial to investigate the analgesic effect of Aspirin during the application of 8% capsaicin
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Age: 18-65 years,
- •Healthy males
- •No history of clinically relevant previous diseases
- •Normal laboratory parameters
- •Normal blood pressure
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 22
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Kidney and liver diseases
- •Gastric and duodenal ulcerations
- •Recent gastritis
- •Diseases of the skin, in particular in the treatment area
- •Infectious diseases
- •Regular intake of analgesics, centrally acting drugs or anti-coagulants
- •Pain on the day of treatment
- •Use of analgesics on the day of treatment
- •Infectious disease on the day of treatment
- •Allergies to any of the study medication
- •Allergic asthma
- •Any surgical procedures planned during the next week after treatment
研究者
相似试验
进行中（未招募）
1 期
A phase III placebo-controlled efficacy and safety study of mocravimod as an adjunctive and maintenance treatment in AML patients undergoing allo-HCT (MO-TRANS Study)Adjunctive and maintenance treatment to HCTMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002864-36-DEPriothera S.A.S.249
招募中
3 期
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCTAacute myeloid leukemia (AML)JPRN-jRCT2011230008Kueenburg Elisabeth30
进行中（未招募）
1 期
A phase IIb placebo-controlled efficacy and safety study of mocravimod as an adjunctive and maintenance treatment in AML patients undergoing allo-HSCT (MO-TRANS Study)Adjunctive and maintenance treatment to HSCTMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2021-002864-36-ESPriothera S.A.S.249
进行中（未招募）
1 期
A phase III placebo-controlled efficacy and safety study of mocravimod as an adjunctive and maintenance treatment in AML patients undergoing allo-HCT (MO-TRANS Study)CTIS2024-512752-38-00Priothera S.A.S.281
进行中（未招募）
1 期
A phase IIb placebo-controlled efficacy and safety study of mocravimod in AML patients undergoing HSCTPatients undergoing allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML)MedDRA version: 20.1Level: PTClassification code 10018651Term: Graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersEUCTR2021-002864-36-FRPriothera S.A.S.160